⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201085 | 1.00 | — | — | |
| Bromide SCHEMBL11700455 | 0.98 | ALDH1A1 (0.39) | — | |
| SCHEMBL27652213 | 0.82 | ALDH1A1 (0.38) | — | |
| SCHEMBL3087900 | 0.79 | — | — | |
| SCHEMBL19743753 | 0.79 | — | — | |
| SCHEMBL7062239 | 0.79 | — | — | |
| SCHEMBL29487561 | 0.79 | — | — | |
| SCHEMBL7331737 | 0.79 | — | — | |
| SCHEMBL10041246 | 0.79 | — | — | |
| SCHEMBL31420239 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096445-A1 | SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF MACROCYCLIC COMPOUNDS | ALKERMES, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| CN-116655526-B | Method for synthesizing 3-bromo-2- (bromomethyl) pyridine | 济南泺合医药技术有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-116655526-A | Method for synthesizing 3-bromo-2- (bromomethyl) pyridine | 济南泺合医药技术有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4329877-B1 | SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY | ALKERMES INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-01-01 | — | — | US | disclosed |
| EP-4647433-A1 | SHP2 INHIBITOR AND USES THEREOF | Kanaph Therapeutics Inc. (KR) | 2025-11-12 | — | — | EP | disclosed |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-10-14 | — | — | US | disclosed |
| EP-4628167-A2 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | Alkermes, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4622712-A1 | SUBSTITUTED MACROCYCLIC AMINE MODULATORS OF OREXIN RECEPTOR 2 | Vertex Pharmaceuticals Incorporated (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20070060594-A1 | Pyridinyl acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-03-15 | — | — | US | disclosed |
| US-20070060594-A1 | Pyridinyl acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-03-15 | — | — | US | disclosed |
| US-20070060594-A1 | Pyridinyl acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-03-15 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1633363-A1 | PYRIDINYL ACETONITRILES | Applied Research Systems ARS Holding N.V. (AN) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2004098607-A1 | PYRIDINYL ACETONITRILES | APPLIED RESEARCH SYSTEMS ARS HOLDING N. V. (AN) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004098607-A1 | PYRIDINYL ACETONITRILES | APPLIED RESEARCH SYSTEMS ARS HOLDING N. V. (AN) | 2004-11-18 | — | — | WO | disclosed |
| US-4018928-A | INHIBITORS OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |